|
1
|
Miller KD, Nogueira L, Devasia T, Mariotto
AB, Yabroff KR, Jemal A, Kramer J and Siegel RL: Cancer treatment
and survivorship statistics, 2022. CA Cancer J Clin. 72:409–436.
2022.PubMed/NCBI
|
|
2
|
GBD 2019 Cancer Risk Factors
Collaborators: The global burden of cancer attributable to risk
factors, 2010-19: A systematic analysis for the global burden of
disease study 2019. Lancet. 400:563–591. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Global Burden of Disease 2019 Cancer
Collaboration; Kocarnik JM, Compton K, Dean FE, Fu W, Gaw BL,
Harvey JD, Henrikson HJ, Lu D, Pennini A, et al: Cancer incidence,
mortality, years of life lost, years lived with disability, and
disability-adjusted life years for 29 cancer groups from 2010 to
2019: A systematic analysis for the global burden of disease study
2019. JAMA Oncol. 8:420–444. 2022. View Article : Google Scholar :
|
|
4
|
Curigliano G, Cardinale D, Dent S,
Criscitiello C, Aseyev O, Lenihan D and Cipolla CM: Cardiotoxicity
of anticancer treatments: Epidemiology, detection, and management.
CA Cancer J Clin. 66:309–325. 2016.PubMed/NCBI
|
|
5
|
Zamorano JL, Lancellotti P, Rodriguez
Muñoz D, Aboyans V, Asteggiano R, Galderisi M, Habib G, Lenihan DJ,
Lip GYH, Lyon AR, et al: 2016 ESC position paper on cancer
treatments and cardiovascular toxicity developed under the auspices
of the ESC committee for practice guidelines: The task force for
cancer treatments and cardiovascular toxicity of the european
society of cardiology (ESC). Eur Heart J. 37:2768–2801. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Swain SM, Whaley FS and Ewer MS:
Congestive heart failure in patients treated with doxorubicin: A
retrospective analysis of three trials. Cancer. 97:2869–2879. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lyu YL, Kerrigan JE, Lin CP, Azarova AM,
Tsai YC, Ban Y and Liu LF: Topoisomerase IIbeta mediated DNA
double-strand breaks: Implications in doxorubicin cardiotoxicity
and prevention by dexrazoxane. Cancer Res. 67:8839–8846. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Shaikh F, Dupuis LL, Alexander S, Gupta A,
Mertens L and Nathan PC: Cardioprotection and second malignant
neoplasms associated with dexrazoxane in children receiving
anthracycline chemotherapy: A systematic review and meta-analysis.
J Natl Cancer Inst. 108:djv3572015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chen Y, Shi S and Dai Y: Research progress
of therapeutic drugs for doxorubicin-induced cardiomyopathy. Biomed
Pharmacother. 156:1139032022. View Article : Google Scholar
|
|
10
|
Wallace KB, Sardão VA and Oliveira PJ:
Mitochondrial determinants of doxorubicin-induced cardiomyopathy.
Circ Res. 126:926–941. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bartlett JJ, Trivedi PC and Pulinilkunnil
T: Autophagic dysregulation in doxorubicin cardiomyopathy. J Mol
Cell Cardiol. 104:1–8. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bayer AL, Zambrano MA, Smolgovsky S, Robbe
ZL, Ariza A, Kaur K, Sawden M, Avery A, London C, Asnani A and
Alcaide P: Cytotoxic T cells drive doxorubicin-induced cardiac
fibrosis and systolic dysfunction. Nat Cardiovasc Res. 3:970–986.
2024. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhao P, Li Y, Xu X, Yang H, Li X, Fu S,
Guo Z, Zhang J, Li H and Tian J: Neutrophil extracellular traps
mediate cardiomyocyte ferroptosis via the Hippo-Yap pathway to
exacerbate doxorubicin-induced cardiotoxicity. Cell Mol Life Sci.
81:1222024. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Bhagat A, Shrestha P and Kleinerman ES:
The innate immune system in cardiovascular diseases and its role in
doxorubicin-induced cardiotoxicity. Int J Mol Sci. 23:146492022.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hutchins E, Yang EH and Stein-Merlob AF:
Inflammation in chemotherapy-induced cardiotoxicity. Curr Cardiol
Rep. 26:1329–1340. 2024. View Article : Google Scholar :
|
|
16
|
Christidi E and Brunham LR: Regulated cell
death pathways in doxorubicin-induced cardiotoxicity. Cell Death
Dis. 12:3392021. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Huang C, Li X, Li H, Chen R, Li Z, Li D,
Xu X, Zhang G, Qin L, Li B and Chu XM: Role of gut microbiota in
doxorubicin-induced cardiotoxicity: From pathogenesis to related
interventions. J Transl Med. 22:4332024. View Article : Google Scholar :
|
|
18
|
Pohjoismäki JL and Goffart S: The role of
mitochondria in cardiac development and protection. Free Radic Biol
Med. 106:345–354. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lopaschuk GD, Karwi QG, Tian R, Wende AR
and Abel ED: Cardiac energy metabolism in heart failure. Circ Res.
128:1487–1513. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Greenwell AA, Gopal K and Ussher JR:
Myocardial energy metabolism in non-ischemic cardiomyopathy. Front
Physiol. 11:5704212020. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Schirone L, D'Ambrosio L, Forte M,
Genovese R, Schiavon S, Spinosa G, Iacovone G, Valenti V, Frati G
and Sciarretta S: Mitochondria and doxorubicin-induced
cardiomyopathy: A complex interplay. Cells. 11:20002022. View Article : Google Scholar :
|
|
22
|
Marques-Aleixo I, Santos-Alves E, Oliveira
PJ, Moreira PI, Magalhães J and Ascensão A: The beneficial role of
exercise in mitigating doxorubicin-induced Mitochondrionopathy.
Biochim Biophys Acta Rev Cancer. 1869:189–199. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
He Y, Huang W, Zhang C, Chen L, Xu R, Li
N, Wang F, Han L, Yang M and Zhang D: Energy metabolism disorders
and potential therapeutic drugs in heart failure. Acta Pharm Sin B.
11:1098–1116. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Bornstein MR, Tian R and Arany Z: Human
cardiac metabolism. Cell Metab. 36:1456–1481. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ritterhoff J and Tian R: Metabolic
mechanisms in physiological and pathological cardiac hypertrophy:
New paradigms and challenges. Nat Rev Cardiol. 20:812–829. 2023.
View Article : Google Scholar
|
|
26
|
Lam CK and Wu JC: Clinical trial in a
dish: Using patient-derived induced pluripotent stem cells to
identify risks of drug-induced cardiotoxicity. Arterioscler Thromb
Vasc Biol. 41:1019–1031. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Xue Z, Zhuo L, Zhang B, Zhu L, Xiang X,
Zhang C, Liu W, Tan G and Liao W: Untargeted metabolomics reveals
the combination effects and mechanisms of Huangqi-fuzi herb-pair
against doxorubicin-induced cardiotoxicity. J Ethnopharmacol.
305:1161092023. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Díaz-Guerra A, Villena-Gutiérrez R,
Clemente-Moragón A, Gómez M, Oliver E, Fernández-Tocino M,
Galán-Arriola C, Cádiz L and Ibáñez B: Anthracycline cardiotoxicity
induces progressive changes in myocardial metabolism and
mitochondrial quality control: novel therapeutic target. JACC
CardioOncol. 6:217–232. 2024. View Article : Google Scholar
|
|
29
|
Tokarska-Schlattner M, Zaugg M, Zuppinger
C, Wallimann T and Schlattner U: New insights into
doxorubicin-induced cardiotoxicity: The critical role of cellular
energetics. J Mol Cell Cardiol. 41:389–405. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Chen X, Wu H, Liu Y, Liu L, Houser SR and
Wang WE: Metabolic reprogramming: A byproduct or a driver of
cardiomyocyte proliferation? Circulation. 149:1598–1610. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hrelia S, Fiorentini D, Maraldi T,
Angeloni C, Bordoni A, Biagi PL and Hakim G: Doxorubicin induces
early lipid peroxidation associated with changes in glucose
transport in cultured cardiomyocytes. Biochim Biophys Acta.
1567:150–156. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Renu K, Vinayagam S, Madhyastha H,
Madhyastha R, Maruyama M, Suman S, Arunachalam S, Vellingiri B and
Valsala Gopalakrishnan A: Exploring the pattern of metabolic
alterations causing energy imbalance via PPARα dysregulation in
cardiac muscle during doxorubicin treatment. Cardiovasc Toxicol.
22:436–461. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Jeyaseelan R, Poizat C, Wu HY and Kedes L:
Molecular mechanisms of doxorubicin-induced cardiomyopathy.
Selective suppression of Reiske iron-sulfur protein, ADP/ATP
translocase, and phosphofructokinase genes is associated with ATP
depletion in rat cardiomyocytes. J Biol Chem. 272:5828–5832. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Liu C, Shen M, Liu Y, Manhas A, Zhao SR,
Zhang M, Belbachir N, Ren L, Zhang JZ, Caudal A, et al: CRISPRi/a
screens in human iPSC-cardiomyocytes identify glycolytic activation
as a druggable target for doxorubicin-induced cardiotoxicity. Cell
Stem Cell. 31:1760–1776.e9. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Bertero E and Maack C: Metabolic
remodelling in heart failure. Nat Rev Cardiol. 15:457–470. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ahmadian M, Suh JM, Hah N, Liddle C,
Atkins AR, Downes M and Evans RM: PPARγ signaling and metabolism:
The good, the bad and the future. Nat Med. 19:557–566. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Loke YK, Kwok CS and Singh S: Comparative
cardiovascular effects of thiazolidinediones: Systematic review and
meta-analysis of observational studies. BMJ. 342:d13092011.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Lopaschuk GD, Ussher JR, Folmes CD, Jaswal
JS and Stanley WC: Myocardial fatty acid metabolism in health and
disease. Physiol Rev. 90:207–258. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Abdel-aleem S, el-Merzabani MM,
Sayed-Ahmed M, Taylor DA and Lowe JE: Acute and chronic effects of
adriamycin on fatty acid oxidation in isolated cardiac myocytes. J
Mol Cell Cardiol. 29:789–797. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Yang Y, Zhang H, Li X, Yang T and Jiang Q:
Effects of PPARα/PGC-1α on the myocardial energy metabolism during
heart failure in the doxorubicin induced dilated cardiomyopathy in
mice. Int J Clin Exp Med. 7:2435–2442. 2014.
|
|
41
|
Kim TT and Dyck JRB: Is AMPK the savior of
the failing heart? Trends Endocrinol Metab. 26:40–48. 2015.
View Article : Google Scholar
|
|
42
|
Schwenk RW, Dirkx E, Coumans WA, Bonen A,
Klip A, Glatz JF and Luiken JJ: Requirement for distinct
vesicle-associated membrane proteins in insulin- and AMP-activated
protein kinase (AMPK)-induced translocation of GLUT4 and CD36 in
cultured cardiomyocytes. Diabetologia. 53:2209–2219. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Hardie DG: AMP-activated protein kinase: A
master switch in glucose and lipid metabolism. Rev Endocr Metab
Disord. 5:119–125. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Folmes CDL and Lopaschuk GD: Role of
malonyl-CoA in heart disease and the hypothalamic control of
obesity. Cardiovasc Res. 73:278–287. 2007. View Article : Google Scholar
|
|
45
|
Tokarska-Schlattner M, Zaugg M, da Silva
R, Lucchinetti E, Schaub MC, Wallimann T and Schlattner U: Acute
toxicity of doxorubicin on isolated perfused heart: Response of
kinases regulating energy supply. Am J Physiol Heart Circ Physiol.
289:H37–H47. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Timm KN and Tyler DJ: The role of AMPK
activation for cardioprotection in doxorubicin-induced
cardiotoxicity. Cardiovasc Drugs Ther. 34:255–269. 2020. View Article : Google Scholar :
|
|
47
|
Puchalska P and Crawford PA:
Multi-dimensional roles of ketone bodies in fuel metabolism,
signaling, and therapeutics. Cell Metab. 25:262–284. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Kashiwaya Y, Sato K, Tsuchiya N, Thomas S,
Fell DA, Veech RL and Passonneau JV: Control of glucose utilization
in working perfused rat heart. J Biol Chem. 269:25502–25514. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Aubert G, Martin OJ, Horton JL, Lai L,
Vega RB, Leone TC, Koves T, Gardell SJ, Krüger M, Hoppel CL, et al:
The failing heart relies on ketone bodies as a fuel. Circulation.
133:698–705. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Selvaraj S, Kelly DP and Margulies KB:
Implications of altered ketone metabolism and therapeutic ketosis
in heart failure. Circulation. 141:1800–1812. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Nielsen R, Møller N, Gormsen LC, Tolbod
LP, Hansson NH, Sorensen J, Harms HJ, Frøkiær J, Eiskjaer H,
Jespersen NR, et al: Cardiovascular effects of treatment with the
ketone body 3-hydroxybutyrate in chronic heart failure patients.
Circulation. 139:2129–2141. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Horton JL, Davidson MT, Kurishima C, Vega
RB, Powers JC, Matsuura TR, Petucci C, Lewandowski ED, Crawford PA,
Muoio DM, et al: The failing heart utilizes 3-hydroxybutyrate as a
metabolic stress defense. JCI Insight. 4:e1240792019. View Article : Google Scholar :
|
|
53
|
Matsuura TR, Puchalska P, Crawford PA and
Kelly DP: Ketones and the heart: Metabolic principles and
therapeutic implications. Circ Res. 132:882–898. 2023. View Article : Google Scholar :
|
|
54
|
Deng Y, Xie M, Li Q, Xu X, Ou W, Zhang Y,
Xiao H, Yu H, Zheng Y, Liang Y, et al: Targeting
mitochondria-inflammation circuit by beta-hydroxybutyrate mitigates
HFpEF. Circ Res. 128:232–245. 2021. View Article : Google Scholar
|
|
55
|
Liu Y, Wei X, Wu M, Xu J, Xu B and Kang L:
Cardioprotective roles of β-hydroxybutyrate against doxorubicin
induced cardiotoxicity. Front Pharmacol. 11:6035962020. View Article : Google Scholar
|
|
56
|
McGarrah RW and White PJ: Branched-chain
amino acids in cardiovascular disease. Nat Rev Cardiol. 20:77–89.
2023. View Article : Google Scholar
|
|
57
|
Quitter F, Figulla HR, Ferrari M, Pernow J
and Jung C: Increased arginase levels in heart failure represent a
therapeutic target to rescue microvascular perfusion. Clin
Hemorheol Microcirc. 54:75–85. 2013. View Article : Google Scholar
|
|
58
|
Navik U, Sheth VG, Kabeer SW and Tikoo K:
Dietary supplementation of methyl donor l-methionine alters
epigenetic modification in type 2 diabetes. Mol Nutr Food Res.
63:e18014012019. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Xin Y, Zhang Y, Yuan Z and Li S:
Methionine is an essential amino acid in doxorubicin-induced
cardiotoxicity through modulating mitophagy. Free Radic Biol Med.
232:28–39. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Nolfi-Donegan D, Braganza A and Shiva S:
Mitochondrial electron transport chain: Oxidative phosphorylation,
oxidant production, and methods of measurement. Redox Biol.
37:1016742020. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Dorn GW II: Mitochondrial dynamism and
heart disease: Changing shape and shaping change. EMBO Mol Med.
7:865–877. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Peoples JN, Saraf A, Ghazal N, Pham TT and
Kwong JQ: Mitochondrial dysfunction and oxidative stress in heart
disease. Exp Mol Med. 51:1–13. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Cheung KG, Cole LK, Xiang B, Chen K, Ma X,
Myal Y, Hatch GM, Tong Q and Dolinsky VW: Sirtuin-3 (SIRT3) protein
attenuates doxorubicin-induced oxidative stress and improves
mitochondrial respiration in H9c2 cardiomyocytes. J Biol Chem.
290:10981–10993. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Yang M, Abudureyimu M, Wang X, Zhou Y,
Zhang Y and Ren J: PHB2 ameliorates doxorubicin-induced
cardiomyopathy through interaction with NDUFV2 and restoration of
mitochondrial complex I function. Redox Biol. 65:1028122023.
View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Zhang P, Chen Z, Lu D, Wu Y, Fan M, Qian J
and Ge J: Overexpression of COX5A protects H9c2 cells against
doxorubicin-induced cardiotoxicity. Biochem Biophys Res Commun.
524:43–49. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Wei Y, Chiang WC, Sumpter R Jr, Mishra P
and Levine B: Prohibitin 2 is an inner mitochondrial membrane
mitophagy receptor. Cell. 168:224–238.e10. 2017. View Article : Google Scholar :
|
|
67
|
Berthiaume JM and Wallace KB:
Adriamycin-induced oxidative mitochondrial cardiotoxicity. Cell
Biol Toxicol. 23:15–25. 2007. View Article : Google Scholar
|
|
68
|
Stockwell BR: Ferroptosis turns 10:
Emerging mechanisms, physiological functions, and therapeutic
applications. Cell. 185:2401–2421. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Hirschhorn T and Stockwell BR: The
development of the concept of ferroptosis. Free Radic Biol Med.
133:130–143. 2019. View Article : Google Scholar :
|
|
70
|
Fang X, Wang H, Han D, Xie E, Yang X, Wei
J, Gu S, Gao F, Zhu N, Yin X, et al: Ferroptosis as a target for
protection against cardiomyopathy. Proc Natl Acad Sci USA.
116:2672–2680. 2019. View Article : Google Scholar :
|
|
71
|
Wu L, Zhang Y, Wang G and Ren J: Molecular
mechanisms and therapeutic targeting of ferroptosis in
doxorubicin-induced cardiotoxicity. JACC Basic Transl Sci.
9:811–826. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Yi X, Wang Q, Zhang M, Shu Q and Zhu J:
Ferroptosis: A novel therapeutic target of natural products against
doxorubicin-induced cardiotoxicity. Biomed Pharmacother.
178:1172172024. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Stěrba M, Popelová O, Vávrová A, Jirkovský
E, Kovaříková P, Geršl V and Simůnek T: Oxidative stress, redox
signaling, and metal chelation in anthracycline cardiotoxicity and
pharmacological cardioprotection. Antioxid Redox Signal.
18:899–929. 2013. View Article : Google Scholar
|
|
74
|
Ji Y, Jin D, Qi J, Wang X, Zhang C, An P,
Luo Y and Luo J: Fucoidan protects against doxorubicin-induced
cardiotoxicity by reducing oxidative stress and preventing
mitochondrial function injury. Int J Mol Sci. 23:106852022.
View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Picca A, Mankowski RT, Burman JL, Donisi
L, Kim JS, Marzetti E and Leeuwenburgh C: Mitochondrial quality
control mechanisms as molecular targets in cardiac ageing. Nat Rev
Cardiol. 15:543–554. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Wu L, Wang L, Du Y, Zhang Y and Ren J:
Mitochondrial quality control mechanisms as therapeutic targets in
doxorubicin-induced cardiotoxicity. Trends Pharmacol Sci. 44:34–49.
2023. View Article : Google Scholar
|
|
77
|
Sahin E, Colla S, Liesa M, Moslehi J,
Müller FL, Guo M, Cooper M, Kotton D, Fabian AJ, Walkey C, et al:
Telomere dysfunction induces metabolic and mitochondrial
compromise. Nature. 470:359–365. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Lagouge M, Argmann C, Gerhart-Hines Z,
Meziane H, Lerin C, Daussin F, Messadeq N, Milne J, Lambert P,
Elliott P, et al: Resveratrol improves mitochondrial function and
protects against metabolic disease by activating SIRT1 and
PGC-1alpha. Cell. 127:1109–1122. 2006. View Article : Google Scholar
|
|
79
|
Herzig S and Shaw RJ: AMPK: Guardian of
metabolism and mitochondrial homeostasis. Nat Rev Mol Cell Biol.
19:121–135. 2018. View Article : Google Scholar :
|
|
80
|
Jäger S, Handschin C, St-Pierre J and
Spiegelman BM: AMP-activated protein kinase (AMPK) action in
skeletal muscle via direct phosphorylation of PGC-1alpha. Proc Natl
Acad Sci USA. 104:12017–12022. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Guberman M, Dhingra R, Cross J, Margulets
V, Gang H, Rabinovich-Nikitin I and Kirshenbaum LA: IKKβ stabilizes
mitofusin 2 and suppresses doxorubicin cardiomyopathy. Cardiovasc
Res. 120:164–173. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Maneechote C, Chattipakorn SC and
Chattipakorn N: Recent advances in mitochondrial
fission/fusion-targeted therapy in doxorubicin-induced
cardiotoxicity. Pharmaceutics. 15:11822023. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Giacomello M, Pyakurel A, Glytsou C and
Scorrano L: The cell biology of mitochondrial membrane dynamics.
Nat Rev Mol Cell Biol. 21:204–224. 2020. View Article : Google Scholar
|
|
84
|
Chen W, Zhao H and Li Y: Mitochondrial
dynamics in health and disease: Mechanisms and potential targets.
Signal Transduct Target Ther. 8:3332023. View Article : Google Scholar :
|
|
85
|
Xia Y, Chen Z, Chen A, Fu M, Dong Z, Hu K,
Yang X, Zou Y, Sun A, Qian J and Ge J: LCZ696 improves cardiac
function via alleviating Drp1-mediated mitochondrial dysfunction in
mice with doxorubicin-induced dilated cardiomyopathy. J Mol Cell
Cardiol. 108:138–148. 2017. View Article : Google Scholar
|
|
86
|
Ding M, Shi R, Cheng S, Li M, De D, Liu C,
Gu X, Li J, Zhang S, Jia M, et al: Mfn2-mediated mitochondrial
fusion alleviates doxorubicin-induced cardiotoxicity with enhancing
its anticancer activity through metabolic switch. Redox Biol.
52:1023112022. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
He W, Wang J, He W, Zeng L, Zhao R, Qiu K,
Tong G, Sun Z and He P: PGAM5 aggravated doxorubicin-induced
cardiotoxicity by disturbing mitochondrial dynamics and
exacerbating cardiomyocytes apoptosis. Free Radic Biol Med.
235:95–108. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Youle RJ and Narendra DP: Mechanisms of
mitophagy. Nat Rev Mol Cell Biol. 12:9–14. 2011. View Article : Google Scholar
|
|
89
|
Ajoolabady A, Chiong M, Lavandero S,
Klionsky DJ and Ren J: Mitophagy in cardiovascular diseases:
Molecular mechanisms, pathogenesis, and treatment. Trends Mol Med.
28:836–849. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Wang S, Long H, Hou L, Feng B, Ma Z, Wu Y,
Zeng Y, Cai J, Zhang DW and Zhao G: The mitophagy pathway and its
implications in human diseases. Signal Transduct Target Ther.
8:3042023. View Article : Google Scholar
|
|
91
|
Hoshino A, Mita Y, Okawa Y, Ariyoshi M,
Iwai-Kanai E, Ueyama T, Ikeda K, Ogata T and Matoba S: Cytosolic
p53 inhibits Parkin-mediated mitophagy and promotes mitochondrial
dysfunction in the mouse heart. Nat Commun. 4:23082013. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Dhingra R, Margulets V, Chowdhury SR,
Thliveris J, Jassal D, Fernyhough P, Dorn GW II and Kirshenbaum LA:
Bnip3 mediates doxorubicin-induced cardiac myocyte necrosis and
mortality through changes in mitochondrial signaling. Proc Natl
Acad Sci USA. 111:E5537–E5544. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Wang P, Wang L, Lu J, Hu Y, Wang Q, Li Z,
Cai S, Liang L, Guo K, Xie J, et al: SESN2 protects against
doxorubicin-induced cardiomyopathy via rescuing mitophagy and
improving mitochondrial function. J Mol Cell Cardiol. 133:125–137.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
He W, Sun Z, Tong G, Zeng L, He W, Chen X,
Zhen C, Chen P, Tan N and He P: FUNDC1 alleviates
doxorubicin-induced cardiotoxicity by restoring
mitochondrial-endoplasmic reticulum contacts and blocked autophagic
flux. Theranostics. 14:3719–3738. 2024. View Article : Google Scholar :
|
|
95
|
Yu W, Deng D, Li Y, Ding K, Qian Q, Shi H,
Luo Q, Cai J and Liu J: Cardiomyocyte-specific Tbk1 deletion
aggravated chronic doxorubicin cardiotoxicity via inhibition of
mitophagy. Free Radic Biol Med. 222:244–258. 2024. View Article : Google Scholar
|
|
96
|
Lu L, Shao Y, Wang N, Xiong X, Zhai M,
Tang J, Liu Y, Yang J and Yang L: Follistatin-like protein 1
attenuates doxorubicin-induced cardiomyopathy by inhibiting
MsrB2-mediated mitophagy. Mol Cell Biochem. 479:1817–1831. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Zhang H, Xie S and Deng W: Mitophagy in
doxorubicin-induced cardiotoxicity: Insights into molecular biology
and novel therapeutic strategies. Biomolecules. 14:16142024.
View Article : Google Scholar :
|
|
98
|
Ky B, Putt M, Sawaya H, French B, Januzzi
JL Jr, Sebag IA, Plana JC, Cohen V, Banchs J, Carver JR, et al:
Early increases in multiple biomarkers predict subsequent
cardiotoxicity in patients with breast cancer treated with
doxorubicin, taxanes, and trastuzumab. J Am Coll Cardiol.
63:809–816. 2014. View Article : Google Scholar
|
|
99
|
Griffiths WJ, Koal T, Wang Y, Kohl M, Enot
DP and Deigner HP: Targeted metabolomics for biomarker discovery.
Angew Chem Int Ed Engl. 49:5426–5445. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Singh A, Bakhtyar M, Jun SR, Boerma M, Lan
RS, Su LJ, Makhoul S and Hsu PC: A narrative review of metabolomics
approaches in identifying biomarkers of doxorubicin-induced
cardiotoxicity. Metabolomics. 21:682025. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Asnani A, Shi X, Farrell L, Lall R, Sebag
IA, Plana JC, Gerszten RE and Scherrer-Crosbie M: Changes in citric
acid cycle and nucleoside metabolism are associated with
anthracycline cardiotoxicity in patients with breast cancer. J
Cardiovasc Transl Res. 13:349–356. 2020. View Article : Google Scholar
|
|
102
|
Thonusin C, Osataphan N, Leemasawat K,
Nawara W, Sriwichaiin S, Supakham S, Gunaparn S, Apaijai N,
Somwangprasert A, Phrommintikul A, et al: Changes in blood
metabolomes as potential markers for severity and prognosis in
doxorubicin-induced cardiotoxicity: A study in HER2-positive and
HER2-negative breast cancer patients. J Transl Med. 22:3982024.
View Article : Google Scholar :
|
|
103
|
Finkelman BS, Putt M, Wang T, Wang L,
Narayan H, Domchek S, DeMichele A, Fox K, Matro J, Shah P, et al:
Arginine-nitric oxide metabolites and cardiac dysfunction in
patients with breast cancer. J Am Coll Cardiol. 70:152–162. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Thonusin C, Nawara W, Khuanjing T,
Prathumsup N, Arinno A, Ongnok B, Arunsak B, Sriwichaiin S,
Chattipakorn SC and Chattipakorn N: Blood metabolomes as
non-invasive biomarkers and targets of metabolic interventions for
doxorubicin and trastuzumab-induced cardiotoxicity. Arch Toxicol.
97:603–618. 2023. View Article : Google Scholar
|
|
105
|
Choksey A and Timm KN: Cancer
therapy-induced cardiotoxicity-a metabolic perspective on
pathogenesis, diagnosis and therapy. Int J Mol Sci. 23:4412021.
View Article : Google Scholar
|
|
106
|
Bauckneht M, Ferrarazzo G, Fiz F, Morbelli
S, Sarocchi M, Pastorino F, Ghidella A, Pomposelli E, Miglino M,
Ameri P, et al: Doxorubicin effect on myocardial metabolism as a
prerequisite for subsequent development of cardiac toxicity: A
translational 18F-FDG PET/CT observation. J Nucl Med.
58:1638–1645. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Seiffert AP, Gómez-Grande A, Castro-Leal
G, Rodríguez A, Palomino-Fernández D, Gómez EJ, Sánchez-González P
and Bueno H: An image processing tool for the detection of
anthracycline-induced cardiotoxicity by evaluating the myocardial
metabolic activity in [18F]FDG PET/CT. Int J Comput
Assist Radiol Surg. 17:373–383. 2022. View Article : Google Scholar
|
|
108
|
Oh CM, Cho S, Jang JY, Kim H, Chun S, Choi
M, Park S and Ko YG: Cardioprotective potential of an SGLT2
inhibitor against doxorubicin-induced heart failure. Korean Circ J.
49:1183–1195. 2019. View Article : Google Scholar :
|
|
109
|
Sabatino J, De Rosa S, Tammè L, Iaconetti
C, Sorrentino S, Polimeni A, Mignogna C, Amorosi A, Spaccarotella
C, Yasuda M and Indolfi C: Empagliflozin prevents
doxorubicin-induced myocardial dysfunction. Cardiovasc Diabetol.
19:662020. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Thirunavukarasu S, Brown LA, Chowdhary A,
Jex N, Swoboda P, Greenwood JP, Plein S and Levelt E: Rationale and
design of the randomised controlled cross-over trial:
Cardiovascular effects of empaglifozin in diabetes mellitus. Diab
Vasc Dis Res. 18:147916412110215852021. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Wang CY, Chen CC, Lin MH, Su HT, Ho MY,
Yeh JK, Tsai ML, Hsieh IC and Wen MS: TLR9 binding to beclin 1 and
mitochondrial SIRT3 by a sodium-glucose co-transporter 2 inhibitor
protects the heart from doxorubicin toxicity. Biology (Basel).
9:3692020.
|
|
112
|
Barış VÖ, Dinçsoy AB, Gedikli E, Zırh S,
Müftüoğlu S and Erdem A: Empagliflozin significantly prevents the
doxorubicin-induced acute cardiotoxicity via non-antioxidant
pathways. Cardiovasc Toxicol. 21:747–758. 2021. View Article : Google Scholar
|
|
113
|
Medina-Her nández D, Cádiz L, Mastrangelo
A, Moreno-Arciniegas A, Fernández Tocino M, Cueto Becerra AA,
Díaz-Guerra Priego A, Skoza WA, Higuero-Verdejo MI, López-Martín
GJ, et al: SGLT2i therapy prevents anthracycline-induced
cardiotoxicity in a large animal model by preserving myocardial
energetics. JACC CardioOncol. 7:171–184. 2025. View Article : Google Scholar
|
|
114
|
Daniele AJ, Gregorietti V, Costa D and
López-Fernández T: Use of EMPAgliflozin in the prevention of
CARDiotoxicity: The EMPACARD-PILOT trial. Cardiooncology.
10:582024.
|
|
115
|
Bhalraam U, Veerni RB, Paddock S, Meng J,
Piepoli M, López-Fernández T, Tsampasian V and Vassiliou VS: Impact
of sodium-glucose cotransporter-2 inhibitors on heart failure
outcomes in cancer patients and survivors: A systematic review and
meta-analysis. Eur J Prev Cardiol. Mar 6–2025.Epub ahead of print.
View Article : Google Scholar
|
|
116
|
Singh M and Jadhav HR: Melatonin:
Functions and ligands. Drug Discov Today. 19:1410–1418. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Govender J, Loos B, Marais E and
Engelbrecht AM: Mitochondrial catastrophe during
doxorubicin-induced cardiotoxicity: A review of the protective role
of melatonin. J Pineal Res. 57:367–380. 2014. View Article : Google Scholar
|
|
118
|
Attachaipanich T, Chattipakorn SC and
Chattipakorn N: Potential roles of melatonin in doxorubicin-induced
cardiotoxicity: From cellular mechanisms to clinical application.
Pharmaceutics. 15:7852023. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Thonusin C, Nawara W, Arinno A, Khuanjing
T, Prathumsup N, Ongnok B, Chattipakorn SC and Chattipakorn N:
Effects of melatonin on cardiac metabolic reprogramming in
doxorubicin-induced heart failure rats: A metabolomics study for
potential therapeutic targets. J Pineal Res. 75:e128842023.
View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Pascale C, Fornengo P, Epifani G, Bosio A
and Giacometto F: Cardioprotection of trimetazidine and
anthracycline-induced acute cardiotoxic effects. Lancet.
359:1153–1154. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Tuunanen H, Engblom E, Naum A, Någren K,
Scheinin M, Hesse B, Juhani Airaksinen KE, Nuutila P, Iozzo P,
Ukkonen H, et al: Trimetazidine, a metabolic modulator, has cardiac
and extracardiac benefits in idiopathic dilated cardiomyopathy.
Circulation. 118:1250–1258. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Chen J, Zhang S, Pan G, Lin L, Liu D, Liu
Z, Mei S, Zhang L, Hu Z, Chen J, et al: Modulatory effect of
metformin on cardiotoxicity induced by doxorubicin via the MAPK and
AMPK pathways. Life Sci. 249:1174982020. View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Foretz M, Guigas B and Viollet B:
Understanding the glucoregulatory mechanisms of metformin in type 2
diabetes mellitus. Nat Rev Endocrinol. 15:569–589. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Kobashigawa LC, Xu YC, Padbury JF, Tseng
YT and Yano N: Metformin protects cardiomyocyte from doxorubicin
induced cytotoxicity through an AMP-activated protein kinase
dependent signaling pathway: An in vitro study. PLoS One.
9:e1048882014. View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Zilinyi R, Czompa A, Czegledi A, Gajtko A,
Pituk D, Lekli I and Tosaki A: The cardioprotective effect of
metformin in doxorubicin-induced cardiotoxicity: The role of
autophagy. Molecules. 23:11842018. View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Onoue T, Kang Y, Lefebvre B, Smith AM,
Denduluri S, Carver J, Fradley MG, Chittams J and Scherrer-Crosbie
M: The association of metformin with heart failure in patients with
diabetes mellitus receiving anthracycline chemotherapy. JACC
CardioOncol. 5:674–682. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
127
|
Serageldin MA, Kassem AB, El-Kerm Y, Helmy
MW, El-Mas MM and El-Bassiouny NA: The effect of metformin on
chemotherapy-induced toxicities in non-diabetic breast cancer
patients: A randomised controlled study. Drug Saf. 46:587–599.
2023. View Article : Google Scholar :
|
|
128
|
Alenghat FJ and Davis AM: Management of
blood cholesterol. JAMA. 321:800–801. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Sun W, Lee TS, Zhu M, Gu C, Wang Y, Zhu Y
and Shyy JY: Statins activate AMP-activated protein kinase in vitro
and in vivo. Circulation. 114:2655–2662. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Yoshida M, Shiojima I, Ikeda H and Komuro
I: Chronic doxorubicin cardiotoxicity is mediated by oxidative DNA
damage-ATM-p53-apoptosis pathway and attenuated by pitavastatin
through the inhibition of Rac1 activity. J Mol Cell Cardiol.
47:698–705. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
131
|
Huelsenbeck J, Henninger C, Schad A,
Lackner KJ, Kaina B and Fritz G: Inhibition of Rac1 signaling by
lovastatin protects against anthracycline-induced cardiac toxicity.
Cell Death Dis. 2:e1902011. View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Al-Kuraishy HM, Al-Gareeb AI, Alkhuriji
AF, Al-Megrin WAI, Elekhnawy E, Negm WA, De Waard M and Batiha GE:
Investigation of the impact of rosuvastatin and telmisartan in
doxorubicin-induced acute cardiotoxicity. Biomed Pharmacother.
154:1136732022. View Article : Google Scholar
|
|
133
|
He H, Wang L, Qiao Y, Yang B, Yin D and He
M: Epigallocatechin-3-gallate pretreatment alleviates
doxorubicin-induced ferroptosis and cardiotoxicity by upregulating
AMPKα2 and activating adaptive autophagy. Redox Biol.
48:1021852021. View Article : Google Scholar
|
|
134
|
Andreadou I, Sigala F, Iliodromitis EK,
Papaefthimiou M, Sigalas C, Aligiannis N, Savvari P, Gorgoulis V,
Papalabros E and Kremastinos DT: Acute doxorubicin cardiotoxicity
is successfully treated with the phytochemical oleuropein through
suppression of oxidative and nitrosative stress. J Mol Cell
Cardiol. 42:549–558. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
135
|
Andreadou I, Mikros E, Ioannidis K, Sigala
F, Naka K, Kostidis S, Farmakis D, Tenta R, Kavantzas N, Bibli SI,
et al: Oleuropein prevents doxorubicin-induced cardiomyopathy
interfering with signaling molecules and cardiomyocyte metabolism.
J Mol Cell Cardiol. 69:4–16. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
136
|
Andreadou I, Papaefthimiou M, Zira A,
Constantinou M, Sigala F, Skaltsounis AL, Tsantili-Kakoulidou A,
Iliodromitis EK, Kremastinos DT and Mikros E: Metabonomic
identification of novel biomarkers in doxorubicin cardiotoxicity
and protective effect of the natural antioxidant oleuropein. NMR
Biomed. 22:585–592. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Singh SK, Yadav P, Patel D, Tanwar SS,
Sherawat A, Khurana A, Bhatti JS and Navik U: Betaine ameliorates
doxorubicin-induced cardiomyopathy by inhibiting oxidative stress,
inflammation, and fibrosis through the modulation of
AMPK/Nrf2/TGF-β expression. Environ Toxicol. 39:4134–4147. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
138
|
Kong L, Liu Y, Wang JH, Lv MJ, Wang YZ,
Sun WP, Cao HM, Guo RB, Zhang L, Yu Y, et al: Linggui Zhugan
decoction ameliorating mitochondrial damage of doxorubicin-induced
cardiotoxicity by modulating the AMPK-FOXO3a pathway targeting
BTG2. Phytomedicine. 139:1565292025. View Article : Google Scholar : PubMed/NCBI
|
|
139
|
Qaed E, Almoiliqy M, Liu W, Al-Mashriqi
HS, Alyafeai E, Aldahmash W, Mahyoub MA and Tang Z: Protective
effects of phosphocreatine against doxorubicin-Induced
cardiotoxicity through mitochondrial function enhancement and
apoptosis suppression via AMPK/PGC-1α signaling pathway. Int
Immunopharmacol. 144:1136772025. View Article : Google Scholar
|
|
140
|
Liu D, Ma Z, Di S, Yang Y, Yang J, Xu L,
Reiter RJ, Qiao S and Yuan J: AMPK/PGC1α activation by melatonin
attenuates acute doxorubicin cardiotoxicity via alleviating
mitochondrial oxidative damage and apoptosis. Free Radic Biol Med.
129:59–72. 2018. View Article : Google Scholar
|
|
141
|
Gharanei M, Hussain A, Janneh O and
Maddock H: Attenuation of doxorubicin-induced cardiotoxicity by
mdivi-1: A mitochondrial division/mitophagy inhibitor. PLoS One.
8:e777132013. View Article : Google Scholar : PubMed/NCBI
|
|
142
|
Dhingra A, Jayas R, Afshar P, Guberman M,
Maddaford G, Gerstein J, Lieberman B, Nepon H, Margulets V, Dhingra
R and Kirshenbaum LA: Ellagic acid antagonizes Bnip3-mediated
mitochondrial injury and necrotic cell death of cardiac myocytes.
Free Radic Biol Med. 112:411–422. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
143
|
Liang X, Wang S, Wang L, Ceylan AF, Ren J
and Zhang Y: Mitophagy inhibitor liensinine suppresses
doxorubicin-induced cardiotoxicity through inhibition of
Drp1-mediated maladaptive mitochondrial fission. Pharmacol Res.
157:1048462020. View Article : Google Scholar : PubMed/NCBI
|
|
144
|
Marechal X, Montaigne D, Marciniak C,
Marchetti P, Hassoun SM, Beauvillain JC, Lancel S and Neviere R:
Doxorubicin-induced cardiac dysfunction is attenuated by
ciclosporin treatment in mice through improvements in mitochondrial
bioenergetics. Clin Sci (Lond). 121:405–413. 2011. View Article : Google Scholar
|
|
145
|
Ding M, Shi R, Fu F, Li M, De D, Du Y and
Li Z: Paeonol protects against doxorubicin-induced cardiotoxicity
by promoting Mfn2-mediated mitochondrial fusion through activating
the PKCε-Stat3 pathway. J Adv Res. 47:151–162. 2023. View Article : Google Scholar
|
|
146
|
Sripusanapan A, Piriyakulthorn C, Apaijai
N, Chattipakorn SC and Chattipakorn N: Ivabradine ameliorates
doxorubicin-induced cardiotoxicity through improving mitochondrial
function and cardiac calcium homeostasis. Biochem Pharmacol.
236:1168812025. View Article : Google Scholar
|
|
147
|
Ge W, Zhang X, Lin J, Wang Y, Zhang X,
Duan Y, Dai X, Zhang J, Zhang Y, Jiang M, et al: Rnd3 protects
against doxorubicin-induced cardiotoxicity through inhibition of
PANoptosis in a Rock1/Drp1/mitochondrial fission-dependent manner.
Cell Death Dis. 16:22025. View Article : Google Scholar : PubMed/NCBI
|
|
148
|
Xu H, Yu W, Sun S, Li C, Zhang Y and Ren
J: Luteolin attenuates doxorubicin-induced cardiotoxicity through
promoting mitochondrial autophagy. Front Physiol. 11:1132020.
View Article : Google Scholar : PubMed/NCBI
|
|
149
|
Li X, Luo W, Tang Y, Wu J, Zhang J, Chen
S, Zhou L, Tao Y, Tang Y, Wang F, et al: Semaglutide attenuates
doxorubicin-induced cardiotoxicity by ameliorating BNIP3-Mediated
mitochondrial dysfunction. Redox Biol. 72:1031292024. View Article : Google Scholar : PubMed/NCBI
|
|
150
|
Maghraby N, El-Baz MAH, Hassan AMA,
Abd-Elghaffar SK, Ahmed AS and Sabra MS: Metformin alleviates
doxorubicin-induced cardiotoxicity via preserving mitochondrial
dynamics balance and calcium homeostasis. Appl Biochem Biotechnol.
197:2713–2733. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
151
|
Zeng X, Zhang H, Xu T, Mei X, Wang X, Yang
Q, Luo Z, Zeng Q, Xu D and Ren H: Vericiguat attenuates
doxorubicin-induced cardiotoxicity through the PRKG1/PINK1/STING
axis. Transl Res. 273:90–103. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
152
|
Wang X, Ma C, Mi K, Cao X, Tan Y, Yuan H,
Ren J and Liang X: Urolithin A attenuates doxorubicin-induced
cardiotoxicity by enhancing PINK1-regulated mitophagy via Ambra1.
Chem Biol Interact. 406:1113632025. View Article : Google Scholar
|
|
153
|
Fu J, Cheng L, Zhang J, Sun R, Yu M, Wu M,
Li S and Cui X: Isoliquiritin targeting m5C RNA methylation
improves mitophagy in doxorubicin-induced myocardial
cardiotoxicity. Phytomedicine. 136:1562932025. View Article : Google Scholar
|
|
154
|
Fiuza-Luces C, Santos-Lozano A, Joyner M,
Carrera-Bastos P, Picazo O, Zugaza JL, Izquierdo M, Ruilope LM and
Lucia A: Exercise benefits in cardiovascular disease: Beyond
attenuation of traditional risk factors. Nat Rev Cardiol.
15:731–743. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
155
|
Naaktgeboren WR, Binyam D, Stuiver MM,
Aaronson NK, Teske AJ, van Harten WH, Groen WG and May AM: Efficacy
of physical exercise to offset anthracycline-induced
cardiotoxicity: A systematic review and meta-analysis of clinical
and preclinical studies. J Am Heart Assoc. 10:e0215802021.
View Article : Google Scholar
|
|
156
|
Antunes P, Joaquim A, Sampaio F, Nunes C,
Ascensão A, Vilela E, Teixeira M, Capela A, Amarelo A, Marques C,
et al: Effects of exercise training on cardiac toxicity markers in
women with breast cancer undergoing chemotherapy with
anthracyclines: A randomized controlled trial. Eur J Prev Cardiol.
30:844–855. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
157
|
Scott JM, Khakoo A, Mackey JR, Haykowsky
MJ, Douglas PS and Jones LW: Modulation of anthracycline-induced
cardiotoxicity by aerobic exercise in breast cancer: Current
evidence and underlying mechanisms. Circulation. 124:642–650. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
158
|
Wang L, Qiao Y, Yu J, Wang Q, Wu X, Cao Q,
Zhang Z, Feng Z and He H: Endurance exercise preconditioning
alleviates ferroptosis induced by doxorubicin-induced
cardiotoxicity through mitochondrial superoxide-dependent AMPKα2
activation. Redox Biol. 70:1030792024. View Article : Google Scholar
|
|
159
|
Suthivanich P, Boonhoh W, Sumneang N,
Punsawad C, Cheng Z and Phungphong S: Aerobic exercise attenuates
doxorubicin-induced cardiomyopathy by suppressing NLRP3
inflammasome activation in a rat model. Int J Mol Sci. 25:96922024.
View Article : Google Scholar :
|
|
160
|
Wang J, Liu S, Meng X, Zhao X, Wang T, Lei
Z, Lehmann HI, Li G, Alcaide P, Bei Y and Xiao J: Exercise inhibits
doxorubicin-induced cardiotoxicity via regulating B cells. Circ
Res. 134:550–568. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
161
|
Ozcan M, Guo Z, Valenzuela Ripoll C, Diab
A, Picataggi A, Rawnsley D, Lotfinaghsh A, Bergom C, Szymanski J,
Hwang D, et al: Sustained alternate-day fasting potentiates
doxorubicin cardiotoxicity. Cell Metab. 35:928–942.e4. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
162
|
Meng Y, Sun J, Zhang G, Yu T and Piao H:
Fasting: A complex, double-edged blade in the battle against
doxorubicin-induced cardiotoxicity. Cardiovasc Toxicol.
24:1395–1409. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
163
|
Cortellino S, Quagliariello V, Delfanti G,
Blaževitš O, Chiodoni C, Maurea N, Di Mauro A, Tatangelo F, Pisati
F, Shmahala A, et al: Fasting mimicking diet in mice delays cancer
growth and reduces immunotherapy-associated cardiovascular and
systemic side effects. Nat Commun. 14:55292023. View Article : Google Scholar : PubMed/NCBI
|
|
164
|
Gao F, Xu T, Zang F, Luo Y and Pan D:
Cardiotoxicity of anticancer drugs: Molecular mechanisms, clinical
management and innovative treatment. Drug Des Devel Ther.
18:4089–4116. 2024. View Article : Google Scholar :
|
|
165
|
Hayashida K, Takegawa R, Shoaib M, Aoki T,
Choudhary RC, Kuschner CE, Nishikimi M, Miyara SJ, Rolston DM,
Guevara S, et al: Mitochondrial transplantation therapy for
ischemia reperfusion injury: A systematic review of animal and
human studies. J Transl Med. 19:2142021. View Article : Google Scholar : PubMed/NCBI
|
|
166
|
Sun M, Jiang W, Mu N, Zhang Z, Yu L and Ma
H: Mitochondrial transplantation as a novel therapeutic strategy
for cardiovascular diseases. J Transl Med. 21:3472023. View Article : Google Scholar : PubMed/NCBI
|
|
167
|
Maleki F, Salimi M, Shirkoohi R and Rezaei
M: Mitotherapy in doxorubicin induced cardiotoxicity: A promising
strategy to reduce the complications of treatment. Life Sci.
304:1207012022. View Article : Google Scholar : PubMed/NCBI
|
|
168
|
Maleki F, Rabbani S, Shirkoohi R and
Rezaei M: Allogeneic mitochondrial transplantation ameliorates
cardiac dysfunction due to doxorubicin: An in vivo study. Biomed
Pharmacother. 168:1156512023. View Article : Google Scholar : PubMed/NCBI
|
|
169
|
Sun X, Chen H, Gao R, Huang Y, Qu Y, Yang
H, Wei X, Hu S, Zhang J, Wang P, et al: Mitochondrial
transplantation ameliorates doxorubicin-induced cardiac dysfunction
via activating glutamine metabolism. iScience. 26:1077902023.
View Article : Google Scholar : PubMed/NCBI
|
|
170
|
Xiong W, Li B, Pan J, Li D, Yuan H, Wan X,
Zhang Y, Fu L, Zhang J, Lei M and Chang ACY: Mitochondrial amount
determines doxorubicin-induced cardiotoxicity in cardiomyocytes.
Adv Sci (Weinh). 12:e24120172025. View Article : Google Scholar : PubMed/NCBI
|
|
171
|
Nencioni A, Caffa I, Cortellino S and
Longo VD: Fasting and cancer: Molecular mechanisms and clinical
application. Nat Rev Cancer. 18:707–719. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
172
|
Yang H, Zingaro VA, Lincoff J, Tom H,
Oikawa S, Oses-Prieto JA, Edmondson Q, Seiple I, Shah H, Kajimura
S, et al: Remodelling of the translatome controls diet and its
impact on tumorigenesis. Nature. 633:189–197. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
173
|
Yang L, TeSlaa T, Ng S, Nofal M, Wang L,
Lan T, Zeng X, Cowan A, McBride M, Lu W, et al: Ketogenic diet and
chemotherapy combine to disrupt pancreatic cancer metabolism and
growth. Med. 3:119–136. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
174
|
Ferrer M, Mourikis N, Davidson EE, Kleeman
SO, Zaccaria M, Habel J, Rubino R, Gao Q, Flint TR, Young L, et al:
Ketogenic diet promotes tumor ferroptosis but induces relative
corticosterone deficiency that accelerates cachexia. Cell Metab.
35:1147–1162.e7. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
175
|
Karlstaedt A, Moslehi J and de Boer RA:
Cardio-oncometabolism: Metabolic remodelling in cardiovascular
disease and cancer. Nat Rev Cardiol. 19:414–425. 2022. View Article : Google Scholar : PubMed/NCBI
|
